Takeda Halts Early R&D Efforts In AAV Gene Therapies And Rare Hematology
Focus On Later-Stage Prospects
The major Japanese firm says decision prompted by desire to focus more resources on late-stage clinical candidates and core therapeutic areas, while expanding deals.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: partial US clinical hold for evobrutinib; Takeda pulls back early AAV gene therapy and rare hematology research; Lilly and Novo shape up for obesity battle; Vir’s new CEO talks to Scrip; and the declining state of pain R&D.
Deal Snapshot: Using antibodies against an undisclosed target discovered and engineered by Innate, Takeda plans to investigate the potential of antibody-drug conjugates in celiac disease
Safety and efficacy data show that as long as Takeda can execute effectively on a Phase III program for TAK-279, the company should be well positioned in the oral psoriasis market.